DIAGNOSTIC & THERAPEUTIC STUDY

- Prostate Cancer Clinical Trial (PSMA-Targeted Diagnostic & Therapeutic Study)
 - Eligibility: Individuals with advanced or metastatic prostate cancer
 - Focus: Precision imaging and investigational PSMA-targeted radiopharmaceuticals
 - Purpose: Evaluate diagnostic accuracy and potential outcomes of targeted radioligand agents
 - Potential Benefit: Early access to study-related evaluations and investigational agents


BENEFITS OF PARTICIPATION:

- 1 Access to advanced imaging and investigational agents.
- Multidisciplinary care led by experienced nuclear medicine specialists.
- Opportunity to contribute to ongoing cancer research under expert supervision.

WHY CHOOSE US?

Excel Diagnostics & Nuclear Oncology Center in Houston, Texas, is offering access to cutting-edge clinical trials for cancer patients. These trials focus on advanced diagnostic and therapeutic approaches to improve outcomes.

- Prostate Cancer Trial:
 Investigating PSMAtargeted imaging and
 therapies.
- 2 Brain Tumor Studies:
 Exploring novel radiolabeled agents for glioblastoma.
- Solid Tumor Research:
 Combining imaging with targeted radiotherapy for various cancers.
- Targeted Alpha Therapy:
 Focused on advanced NET
 tumors and prostate cancer.
 This drug has received break
 through designation by FDA





Excel Diagnostics &Nuclear Oncology Center

ADVANCING CANCER RESEARCH OPPORTUNITIES

DIAGNOSTICS



- Eligibility: Adults with newly diagnosed or recurrent GBM
- Focus: Investigational radiolabeled agents targeting tumor-specific receptors
- Purpose: Assess safety and potential activity of novel therapies in GBM
- Potential Benefit: Contribute to ongoing research in glioblastoma under expert supervision

2 Cu64PSM0003 (Prostate Cancer)

- Eligibility: Individuals with newly diagnosed prostate cancer and Planned Prostatectomy
- Focus: Diagnostics approach for PSMA avid prostate cancer imaging
- Purpose: Investigate tumor imaging and targeted delivery of radiopharmaceuticals
- Potential Benefit: Contribute to ongoing research in prostate cancer under expert supervision



GET IN TOUCH

Refer a patient or contact us to learn more. Help advance cancer research and expand access to innovative diagnostic and therapeutic studies.

OUR CONTACT:



- Ms. Susan Cork
 Therapy Coordinator
 713-204-1333
 Dr. Ebrahim Delpassand
 713-499-9733

www.exceldiagnostics.com

scork@exceldiagnostics.com



THERAPEUTIC TRIALS

- 1 Solid Tumor Clinical Trial (bladder/urothelial, triple-negative breast, colorectal, ovarian, and pancreatic cancers)
 - Eligibility: Individuals with advanced or metastatic solid tumors
 - Focus: Theragnostic approach combining imaging and targeted investigational radiotherapy
 - Purpose: Investigate tumor imaging and targeted delivery of radiopharmaceuticals

2 Targeted Alpha Therapy, Neuroendocrine Tumors

- Eligibility: Individuals with advanced or metastatic NET tumors
- Focus: Theragnostic approach combining imaging and targeted investigational radiotherapy
- Purpose: Investigate tumor imaging and targeted delivery of radiopharmaceuticals This drug has received break through designation by FDA

3 Superscan Study (Prostate Cancer)

- Eligibility: Individuals with Progressive PSMA-Positive Prostate Cancer and Super Scan Bone Scan
- Focus: To assess the feasibility and safety of Lutetium-177-PSMA-617 (PLUVICTO) in mCRPC patients with a super scan on bone imaging
- Purpose: Investigate targeted delivery of radiopharmaceuticals
- Potential Benefit: Contribute to ongoing research in prostate cancer under expert supervision